摘要
不同病理组织学分级滤泡淋巴瘤(FL)呈高度异质性,其生物学特性和临床管理方式存在差异。本研究回顾性分析山西省肿瘤医院161例不同病理组织学分级(1~2级、3A级、3B级)FL患者的^(18)F-氟代脱氧葡萄糖(FDG)PET-CT代谢参数、临床特征及其和预后的关系。病理组织学分级1~2级93例,3A级40例,3B级28例。LDH、CD10、EZH2、c-Myc、CD37蛋白表达与病理组织学分级(1~2级、3A级、3B级)有关(P值均<0.05),三组间的最大标准化摄取值(SUVmax)、糖酵解总量(TLG)、肿瘤-纵隔血池标准化摄取值比(TBR)和肿瘤-肝脏标准化摄取值比(TLR)差异均有统计学意义(P值均<0.05)。SUVmax、肿瘤代谢体积(MTV)、TLG、TBR、TLR预测FL疾病进展最佳界值分别为8.32、201.31、2342.55、6.56、3.52,大于界值组的患者疾病进展率增加(P值均<0.05)。血清β2微球蛋白(>2.3μg/L)、滤泡淋巴瘤国际预后指数(FLIPI-1)评分(3~5分)、CD37蛋白表达阴性、c-Myc蛋白表达阳性、TLG(>2342.55 g)均是影响FL患者无进展生存的独立危险因素(HR=3.609、2.509、0.255、3.506、13.531,P值均<0.05)。^(18)F-FDG PET-CT是FL病理组织学分级的有力补充,两者结合可以更好地预测FL患者的预后。
Follicular lymphoma(FL)is highly heterogeneous with different histopathologic grades.Its biological characteristics and clinical management are different.This study retrospectively analyzed^(18)F-FDG PET-CT metabolic parameters,clinical features,and their relationship with prognosis in 161 FL patients with different histopathological grades(grade 1-2,grade 3A,grade 3B)at the Shanxi Cancer Hospital.There were 93 cases in the grade 1-2 group,40 cases in the grade 3A group,and 28 cases in the grade 3B group.The expression of LDH,CD10,EZH2,c-Myc,and CD37 proteins was correlated with histological grade(grade 1-2,grade 3A,and grade 3B)(all P values<0.05).The SUVmax,TLG,TBR,and TLR for the three groups were different(all P values<0.05).The optimal thresholds of SUVmax,MTV,TLG,TBR,and TLR for predicting FL disease progression were 8.32,201.31,2342.55,6.56,and 3.52,respectively,and the rate of disease progression increased in patients with higher thresholds(all P value<0.05).β2-MG(>2.3μg/L),Follicular lymphoma international prognostic index-1(FLIPI-1)score(3-5 points),negative CD37 expression,positive c-Myc expression,and TLG(>2342.55 g)were all independent risk factors for PFS in the FL patients(HR=3.609,2.509,0.255,3.506,13.531,all P value<0.05).^(18)F-FDG PET-CT is a powerful complement to FL histopathological grading and the combination of the two may better predict the prognosis of FL patients.
作者
赵彤
白敏
王蕊
赵铭
田蓉蓉
邢军
林艳梅
周洁
原凌
Zhao Tong;Bai Min;Wang Rui;Zhao Ming;Tian Rongrong;Xing Jun;Lin Yanmei;Zhou Jie;Yuan Ling(Department of Nuclear Medicine(PET/CT),China Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China;Department of Hematology,China Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China;School of Forensic Medicine,Shanxi Medical University,Taiyuan 030001,China)
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2024年第8期776-780,共5页
Chinese Journal of Hematology
基金
山西省“四个一批”引导性科技专项基金(2021XM49)
山西省自然科学基金(202203021211046)
山西省基础研究青年项目基金(20210302123446)。